Ulcerative Colitis - Current and Future Players, New Report Launched

“PharmaPoint: Ulcerative Colitis - Current and Future Players” report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Ulcerative Colitis Market. The report identifies and analyses the key companies shaping and driving the global Ulcerative Colitis market. The report provides insight into the competitive Ulcerative Colitis landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by Publisher’s team of industry experts.

Scope

• Investigation of current and future market competition for Ulcerative Colitis
• Competitor assessment
• Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
• Strategic assessment of Ulcerative Colitis sector through market impact analysis, future market scenario and company analysis

Reasons to buy

• Gain a high level view of the trends shaping and driving Ulcerative Colitis market
• Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
• Create an effective counter-strategy to gain a competitive advantage against those currently in the market
• What’s the next big thing in the global Ulcerative Colitis market landscape? Identify, understand and capitalize.

Spanning Over 53 pages, “PharmaPoint: Ulcerative Colitis - Current and Future Players” report covering the Market Outlook, Current and Future Players, Appendix. The report covered 9 companies - Johnson & Johnson, AbbVie, Takeda Pharmaceuticals, Warner Chilcott, Salix Pharmaceuticals/Santarus, Shire Pharmaceuticals, Ferring Pharmaceuticals, Pfizer, InDeX Pharmaceuticals

Know more about this report at: http://mrr.cm/ZqL

Find all Diseases Report at: http://www.marketresearchreports.com/diseases

EU5 Nuclear Imaging Equipment Market Outlook to 2020, New Report Launched

"EU5 Nuclear Imaging Equipment Market Outlook to 2020", provides key market data on the EU5 Nuclear Imaging Equipment market. The report provides value, in millions of US dollars, and volume (in units) and average price data (in US dollars), within market categories - Positron Emission Tomography Systems (PET Systems and PET/CT Systems) and Single Photon Emission Computed Tomography Systems (SPECT Systems and SPECT/CT Systems).

The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Nuclear Imaging Equipment market wherever available.

The data in the report is derived from dynamic market forecast models. Publisher uses capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible.

Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases).

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

• Market size for Nuclear Imaging Equipment market categories - Positron Emission Tomography Systems (PET Systems and PET/CT Systems) and Single Photon Emission Computed Tomography Systems (SPECT Systems and SPECT/CT Systems)..
• Annualized market revenues (USD million), volume (units) and average selling price ($) data for each of the market categories. Data is provided from 2005 to 2012 and forecast to 2020.
• 2012 company shares and distribution shares data for each of the market categories.
• Global corporate-level profiles of key companies operating within the EU5 Nuclear Imaging Equipment market.
• Key players covered include GE Healthcare, Philips Healthcare and Siemens Healthcare.

Reasons to buy

• Develop business strategies by identifying the key market segments poised for strong growth in the future.
• Develop market-entry and market expansion strategies.
• Design competition strategies by identifying who-stands-where in the market.
• Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
• What are the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.

Spanning Over 192 pages, “EU5 Nuclear Imaging Equipment Market Outlook to 2020” report covering the Nuclear Imaging Equipment Market, EU5, Nuclear Imaging Equipment Market, France, Nuclear Imaging Equipment Market, Germany, Nuclear Imaging Equipment Market, Italy, Nuclear Imaging Equipment Market, Spain, Nuclear Imaging Equipment Market, United Kingdom, Overview of Key Companies in EU5 Nuclear Imaging Equipment Market, Nuclear Imaging Equipment Market Pipeline Products, Financial Deals Landscape, Recent Developments, Appendix. The report covered 3 companies - GE Healthcare, Siemens Healthcare, Philips Healthcare.

Know more about this report at: http://mrr.cm/Zq2

EU5 Computed Tomography Systems Market Outlook to 2020, New Report Launched

"EU5 Computed Tomography Systems Market Outlook to 2020", provides key market data on the EU5 Computed Tomography Systems market. The report provides value, in millions of US dollars, and volume (in units) and average price data (in US dollars), within market categories - High Slice Computed Tomography Systems, Low Slice Computed Tomography Systems and Mid Slice Computed Tomography Systems.

The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Computed Tomography Systems market wherever available.

The data in the report is derived from dynamic market forecast models. Publisher uses capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible.

Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases).

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

• Market size for Computed Tomography Systems market categories - High Slice Computed Tomography Systems, Low Slice Computed Tomography Systems and Mid Slice Computed Tomography Systems.
• Annualized market revenues (USD million), volume (units) and average selling price ($) data for each of the market categories. Data is provided from 2005 to 2012 and forecast to 2020.
• 2012 company shares and distribution shares data for the market category.
• Global corporate-level profiles of key companies operating within the EU5 Computed Tomography Systems market.
• Key players covered include GE Healthcare, Philips Healthcare, Siemens Healthcare and Toshiba Medical Systems Corporation

Reasons to buy

• Develop business strategies by identifying the key market segments poised for strong growth in the future.
• Develop market-entry and market expansion strategies.
• Design competition strategies by identifying who-stands-where in the market.
• Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
• What are the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.

Spanning Over 122 pages, “EU5 Computed Tomography Systems Market Outlook to 2020” report covering the Computed Tomography Systems Market, EU5, Computed Tomography Systems Market, France, Computed Tomography Systems Market, Germany, Computed Tomography Systems Market, Italy, Computed Tomography Systems Market, Spain, Computed Tomography Systems Market, United Kingdom, Overview of Key Companies in EU5 Computed Tomography Systems Market, Computed Tomography Systems Market Pipeline Products, Financial Deals Landscape, Recent Developments, Appendix. The report covered 4 companies - Siemens Healthcare, GE Healthcare, Philips Healthcare, Toshiba Medical Systems Corporation

Know more about this report at: http://mrr.cm/Zq7

United States External Defibrillators Market Outlook to 2020, New Report Launched

"United States External Defibrillators Market Outlook to 2020", provides key market data on the United States External Defibrillators market. The report provides value, in millions of US dollars, and volume (in units) and average price data (in US dollars), within market categories - Manual Defibrillators, Professional AED and Public Access AED.

The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the External Defibrillators market wherever available.

The data in the report is derived from dynamic market forecast models. Publisher uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible.

The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers.

Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases).

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

• Market size for External Defibrillators categories - Manual Defibrillators, Professional AED and Public Access AED.
• Annualized market revenues (USD million), volume (units) and average selling price ($) data for each of the market categories. Data is provided from 2005 to 2012 and forecast to 2020.
• 2012 company shares and distribution shares data for the market category.
• Global corporate-level profiles of key companies operating within the United States External Defibrillators market.
• Key players covered include ZOLL Medical Corporation, Philips Healthcare, Medtronic, Inc. and Cardiac Science Corporation.

Reasons to buy

• Develop business strategies by identifying the key market categories and segments poised for strong growth in the future.
• Develop market-entry and market expansion strategies.
• Design competition strategies by identifying who-stands-where in the market.
• Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
• What are the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.

Spanning Over 62 pages, “United States External Defibrillators Market Outlook to 2020” report covering the External Defibrillators Market, United States, Overview of Key Companies in United States, External Defibrillators Marke, Financial Deals Landscape, Recent Developments, Appendix. The report covered 6 companies - Philips Healthcare, Zoll Medical Corporation, Physio-Control, Inc., Opto Circuits India Limited, HeartSine Technologies, Inc., Defibtech, LLC

Know more about this report at: http://mrr.cm/Zqd

Asia-Pacific Nuclear Imaging Equipment Market Outlook to 2020, New Report Launched

"Asia-Pacific Nuclear Imaging Equipment Market Outlook to 2020", provides key market data on the Asia-Pacific Nuclear Imaging Equipment market. The report provides value, in millions of US dollars, and volume (in units) and average price data (in US dollars), within market categories - Positron Emission Tomography Systems (PET Systems and PET/CT Systems) and Single Photon Emission Computed Tomography Systems (SPECT Systems and SPECT/CT Systems).

The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Nuclear Imaging Equipment market wherever available.

The data in the report is derived from dynamic market forecast models. Publisher uses capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible.

Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases).

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

• Market size for Nuclear Imaging Equipment market categories - Positron Emission Tomography Systems (PET Systems and PET/CT Systems) and Single Photon Emission Computed Tomography Systems (SPECT Systems and SPECT/CT Systems)..
• Annualized market revenues (USD million), volume (units) and average selling price ($) data for each of the market categories. Data is provided from 2005 to 2012 and forecast to 2020.
• 2012 company shares and distribution shares data for each of the market categories.
• Global corporate-level profiles of key companies operating within the Asia-Pacific Nuclear Imaging Equipment market.
• Key players covered include GE Healthcare, Philips Healthcare and Siemens Healthcare.

Reasons to buy

• Develop business strategies by identifying the key market segments poised for strong growth in the future.
• Develop market-entry and market expansion strategies.
• Design competition strategies by identifying who-stands-where in the market.
• Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
• What are the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.

Spanning Over 184 pages, “Asia-Pacific Nuclear Imaging Equipment Market Outlook to 2020” report covering the Nuclear Imaging Equipment Market, Asia-Pacific, Nuclear Imaging Equipment Market, Australia, Nuclear Imaging Equipment Market, China, Nuclear Imaging Equipment Market, India, Nuclear Imaging Equipment Market, Japan, Nuclear Imaging Equipment Market, South Korea, Overview of Key Companies in Asia-Pacific Nuclear Imaging Equipment Market, Nuclear Imaging Equipment Market Pipeline Products, Financial Deals Landscape, Recent Developments, Appendix. The report covered 4 companies - GE Healthcare, Philips Healthcare, Siemens Healthcare, Shimadzu Corporation.

Know more about this report at: http://mrr.cm/Zqe

Ulcerative Colitis - US Drug Forecast and Market Analysis to 2022, New Report Launched

During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson’s (J&J’s) Simponi and Takeda’s Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.

Publisher estimates that by the end of the forecast period the UC market in the US will grow to approximately $3.5 billion. While the prevalence of the disease in the US will plateau during the course of the 10-year forecast period from 2012-2022, the overall patient numbers are on the rise because of the country’s growing population and increasing life expectancy. This market would grow even more if Remicade and Humira were not set to lose their patent protection in 2018. Biosimilars are expected to eventually take two thirds of their branded drugs’ sales in the US.

Scope

• Overview of Ulcerative Colitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for the top drugs in the US from 2012-2022.
• Analysis of the impact of key events as well the drivers and restraints affecting the US Ulcerative Colitis market.

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for Ulcerative Colitis.
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of drug performance
• Obtain sales forecast for drugs from 2012-2022 in Ulcerative Colitis.

Spanning Over 134 pages, “PharmaPoint: Ulcerative Colitis - US Drug Forecast and Market Analysis to 2022” report covering the Disease Overview, Disease Management, Competitive Assessment, Opportunity and Unmet Need, Pipeline Assessment, Market Outlook, Appendix.

Know more about this report at: http://mrr.cm/Zqf

Ulcerative Colitis - China Drug Forecast and Market Analysis to 2022, New Report Launched

During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson’s (J&J’s) Simponi and Takeda’s Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.

Overprescribing of medicines is common in China, as the revenue generated pays for the few quality hospitals that are available. To prevent overprescribing, the Chinese government recently cut the maximum price of about 1,200 commonly used drugs. Also, as a result of China’s progress in reforming its healthcare system under the Five-Year Plan, basic medical coverage had reached more than 90% of the Chinese by the end of 2011.

Scope

• Overview of Ulcerative Colitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for the top drugs in China from 2012-2022.
• Analysis of the impact of key events as well the drivers and restraints affecting the China Ulcerative Colitis market.

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for Ulcerative Colitis.
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of drug performance
• Obtain sales forecast for drugs from 2012-2022 in Ulcerative Colitis.

Spanning Over 88 pages, “PharmaPoint: Ulcerative Colitis - China Drug Forecast and Market Analysis to 2022” report covering the Disease Overview, Disease Management, Competitive Assessment, Opportunity and Unmet Need, Pipeline Assessment, Market Outlook, Appendix.

Know more about this report at: http://mrr.cm/ZqM

Russia Diagnostic Imaging Market Outlook to 2020, New Report Launched

The report provides key market data on the Russia Diagnostic Imaging market. The report provides value, in millions of US dollars, and volume (in units) within market categories - Angio Suites, Bone Densitometers, C-Arms, Computed Tomography Systems, Contrast Media Injectors, Mammography Equipment, MRI Systems, Nuclear Imaging Equipment, Ultrasound Systems and X-ray Systems.

The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Diagnostic Imaging market wherever available.

The data in the report is derived from dynamic market forecast models. Publisher uses capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible.

Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases).

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

• Market size for Diagnostic Imaging market categories - Angio Suites, Bone Densitometers, C-Arms, Computed Tomography Systems, Contrast Media Injectors, Mammography Equipment, MRI Systems, Nuclear Imaging Equipment, Ultrasound Systems and X-ray Systems.
• Annualized market revenues (USD million) and volume (units) data for each of the market categories. Data is provided from 2005 to 2012 and forecast to 2020.
• 2012 company shares and distribution shares data for the market category.
• Global corporate-level profiles of key companies operating within the Russia Diagnostic Imaging market.
• Key players covered include GE Healthcare, Philips Healthcare, Siemens Healthcare and Toshiba Medical Systems Corporation

Reasons to buy

• Develop business strategies by identifying the key market segments poised for strong growth in the future.
• Develop market-entry and market expansion strategies.
• Design competition strategies by identifying who-stands-where in the market.
• Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
• What are the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.

Spanning Over 177 pages, “Russia Diagnostic Imaging Market Outlook to 2020” report covering Diagnostic Imaging Market, Russia, Angio Suites Market, Russia, Bone Densitometers Market, Russia, C-Arms Market, Russia, Computed Tomography Systems Market, Russia, Contrast Media Injectors Market, Russia, Mammography Equipment Market, Russia, MRI Systems Market, Russia, Nuclear Imaging Equipment Market, Russia, Ultrasound Systems Market, Russia, X-ray Systems Market, Russia, Overview of Key Companies in Russia, Diagnostic Imaging Market, Diagnostic Imaging Market Pipeline Products, Financial Deals Landscape, Recent Developments, Appendix. The report covered 9 companies - GE Healthcare, Siemens Healthcare, Philips Healthcare, Toshiba Medical Systems Corporation, Medical Technologies Ltd., AMICO ELECTRON Ltd., Hitachi Medical Corporation, Esaote S.p.A.

Know more about this report at: http://mrr.cm/ZqG

Find all Medical Devices Reports at : http://www.marketresearchreports.com/medical-devices

Brazil Diagnostic Imaging Market Outlook to 2020, New Report Launched

"Brazil Diagnostic Imaging Market Outlook to 2020", provides key market data on the Brazil Diagnostic Imaging market. The report provides value, in millions of US dollars, and volume (in units) within market categories - Angio Suites, Bone Densitometers, C-Arms, Computed Tomography Systems, Contrast Media Injectors, Mammography Equipment, MRI Systems, Nuclear Imaging Equipment, Ultrasound Systems and X-ray Systems.

The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Diagnostic Imaging market wherever available.

The data in the report is derived from dynamic market forecast models. Publisher uses capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible.

Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases).

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

• Market size for Diagnostic Imaging market categories - Angio Suites, Bone Densitometers, C-Arms, Computed Tomography Systems, Contrast Media Injectors, Mammography Equipment, MRI Systems, Nuclear Imaging Equipment, Ultrasound Systems and X-ray Systems.
• Annualized market revenues (USD million) and volume (units) data for each of the market categories. Data is provided from 2005 to 2012 and forecast to 2020.
• 2012 company shares and distribution shares data for the market category.
• Global corporate-level profiles of key companies operating within the Brazil Diagnostic Imaging market.
• Key players covered include GE Healthcare, Philips Healthcare, Siemens Healthcare and Toshiba Medical Systems Corporation

Reasons to buy

• Develop business strategies by identifying the key market segments poised for strong growth in the future.
• Develop market-entry and market expansion strategies.
• Design competition strategies by identifying who-stands-where in the market.
• Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
• What are the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.

Spanning Over 171 pages, “Brazil Diagnostic Imaging Market Outlook to 2020” report covering Diagnostic Imaging Market, Brazil, Angio Suites Market, Brazil, Bone Densitometers Market, Brazil, C-Arms Market, Brazil, Computed Tomography Systems Market, Brazil, Contrast Media Injectors Market, Brazil, Mammography Equipment Market, Brazil, MRI Systems Market, Brazil, Nuclear Imaging Equipment Market, Brazil, Ultrasound Systems Market, Brazil, X-ray Systems Market, Brazil, Overview of Key Companies in Brazil, Diagnostic Imaging Market, Diagnostic Imaging Market Pipeline Products, Financial Deals Landscape, Recent Developments, Appendix. The report covered 11 companies - GE Healthcare, Siemens Healthcare, Philips Healthcare, Toshiba Medical Systems Corporation, Hitachi Medical Corporation, Samsung Medison Co., Ltd. ,Fujifilm Holdings Corporation, Mindray Medical International Limited ,Shimadzu Corporation, Esaote S.p.A., Hologic, I

Know more about this report at: http://mrr.cm/ZqN

Find all Medical Devices Reports at : http://www.marketresearchreports.com/medical-devices

The global schizophrenia treatment market value is expected to Reach $7.9 billion by 2022, Reveals New Report

Schizophrenia Treatment Market: Novel Products to Provide Slight Boost by 2022, While Unmet Needs Remain, says Publisher

The global schizophrenia treatment market value is expected to undergo a modest increase over the coming decade, climbing from $6.3 billion in 2012 to $7.9 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 2.4%, according to a new report from research and consulting firm by Publisher.

The company’s latest report* states that out of the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK and Japan), the US dominated the schizophrenia space in 2012 with sales of $5.2 billion and a global share of 83%. It will maintain its market-leading position by 2022 with sales of $6.1 billion, representing a CAGR of 1.6% during the forecast period.

Publisher attributes the anticipated market expansion to a rising awareness of mental health, along with increasing utilization of long-acting injectable (LAI) antipsychotics and various new product launches.

Among the drugs that are due to enter the market during the forecast period are Otsuka’s brexpiprazole, Roche/Chugai’s bitopertin, EnVivo’s EVP-6124 and Alkermes’ aripiprazole lauroxil and Invega Sustenna (Three-Month).

According  to  Analyst covering Neurology, “These latter two drugs will introduce new LAI treatments and expand the global market options by 33%. The three-month version of Pfizer’s Invega Sustenna in particular will provide patients with a reduced dosing burden.

“As novel products in an emerging part of the schizophrenia drug market, these agents could be met with significant sales, due to their higher costs of therapy and a growing popularity of LAIs in this space.”

However, such costs may well push patients toward generic alternatives, subsequently hindering any further growth in the global schizophrenia market, according to Publisher.

Furthermore, the level of unmet need in schizophrenia and related mental health disorders is one of the highest in medicine today, presenting another significant barrier to the market.

According  to  Analyst, “Schizophrenia treatment currently consists of first-generation antipsychotics and atypical therapies, which do not adequately satisfy patients’ needs.

“While the pipeline boasts several candidates targeting negative and cognitive symptoms, in addition to a number of LAI therapies, the fierce competition surrounding the schizophrenia market means these products will have to demonstrate that their utility surpasses those of currently marketed options,” the analyst concludes.

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2022 report provides an overview of schizophrenia, including etiology, general symptoms and country-specific treatment recommendations and compliance data. The key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the schizophrenia market.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by Publisher’s team of industry experts.

Know more about this report at: http://mrr.cm/ZqT

Find all Pharma and Healthcare Reports at : http://www.marketresearchreports.com/pharma-healthcare

Gout - Epidemiology Forecast to 2023, New Report Launched

Gout is a type of inflammatory arthritis. The disease is triggered by the crystallization of uric acid within the joints and is associated with hyperuricemia, a condition in which the body either overproduces or under excretes uric acid (Choi et al., 2005a). Attacks of gout are episodic in nature and although months may pass before the next attack occurs, the pain experienced during an attack can be debilitating. Men are at a higher risk for developing gout and the risk also increases with age, with a mean age at diagnosis for gout in both men and women of 61 years (Khanna et al., 2012).

This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for gout in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). In addition, this report includes a 10-year epidemiological forecast for the diagnosed incident cases and the diagnosed prevalent cases of gout segmented by sex and age (in five-year age groups beginning at 20 years and ending at ≥85 years). The diagnosed prevalent cases are then further segmented by the number of cases of gout flares and tophaceous gout.

To build the epidemiological forecast, Publisher epidemiologists used country-specific studies that provided the diagnosed incidence and diagnosed prevalence of gout based on the American College of Rheumatology (ACR) criteria for the clinical diagnosis of gout, or diagnostic codes using the International Classification of Diseases, Ninth Revision (ICD-9), International Classification of Diseases, Tenth Revision (ICD-10), Oxford Medical Information Systems (OXMIS), or READ (the standard clinical terminology system used in the UK). For the US, Publisher epidemiologists used the self-reported diagnosed prevalence of gout from the National Health and Nutrition Examination Survey (NHANES) conducted in 2007-2008.

Publisher epidemiologists forecast an increase in both the diagnosed incident cases and diagnosed prevalent cases of gout in the 6MM, from 1,374,065 diagnosed incident cases in 2013 to 1,649,065 diagnosed incident cases in 2023, at an annual growth rate (AGR) of 2.00%, and 13,750,047 diagnosed prevalent cases in 2013 to 17,625,944 diagnosed prevalent cases in 2023, at an AGR of 2.82%. Throughout the forecast period, the US will have the highest number of diagnosed incident cases and diagnosed prevalent cases of gout, with 949,846 diagnosed incident cases and 11,062,526 diagnosed prevalent cases in 2023.

Know more about this report at: http://mrr.cm/Zqc

Find all Biotechnology Reports at : http://www.marketresearchreports.com/biotechnology

Atrial Fibrillation - Epidemiology Forecast to 2023, New Report Launched

Atrial fibrillation (AF) is a disorder of the heart’s electrical system. The condition is characterized by an irregular heart rhythm that is either too fast or too slow. During AF, the two upper chambers of the heart (atria) beat out of coordination with the two lower chambers (ventricles) due to disorganized electrical signals, resulting in poor blood supply to the lungs and the rest of the body. The symptoms of AF typically include heart palpitations, irregular and fast heartbeat, chest discomfort, shortness of breath, dizziness, and weakness (Mayo Clinic, 2013; NHLBI, 2011). However, individuals with AF may be asymptomatic and not even know that they have the condition until it is identified through an electrocardiogram (EKG or ECG) test.

AF is one of the most common cardiovascular diseases among the elderly, worldwide. Although AF affects people of all ages, the condition is rare in individuals younger than 40 years of age. The risk for AF increases rapidly with age and is more common in men than women. According to the Global Burden of Disease (GBD) study, AF affected approximately 33.5 million persons, or 0.5% of the world's population, in 2010, of which 20.9 million were men and 12.6 million were women (Chugh et al., 2013). The disease burden is likely to increase in the near future due to the projected increase in the population, especially the elderly population (Go et al., 2001; Savelieva and Camm, 2001).

Globally, the prevalence of AF varies widely, depending on the country and the study, ranging from 0.1%-1.6% in Asia (0.1% in India, 1.6% in Japan), 0.95%-3.9% in North America (0.95% in the US, 3.9% in Canada), 1.28%-2.1% in Europe (1.28% in the UK, 2.1% in Germany), and 4.0% in Australia (Ceresne and Upshur, 2002; Go et al., 2001; Iguchi et al., 2008; Kaushal et al., 1995; Majeed et al., 2001; Sturm et al., 2002; Wilke et al., 2013). Due to the asymptomatic nature of the condition, many cases go undetected. Even though the condition itself is not life-threatening, it can be uncomfortable and may require medical attention, as AF increases the risk for stroke and death.

This report provides an overview of the risk factors and comorbidities, as well as the global and historical trends, for AF in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Canada). In addition, this report includes a 10-year epidemiological forecast (2013-2023) for the diagnosed prevalent cases of AF segmented by sex, age (in five-year age groups, beginning at 40 years and ending at ≥85 years), and clinical subtypes (paroxysmal, persistent, and permanent AF) in these markets. To forecast the diagnosed prevalent cases of AF in the 8MM, Publisher epidemiologists used only country-specific studies that provided the diagnosed prevalence of AF using uniform diagnostic criteria based on EKG tests. For Japan, Publisher epidemiologists used an indirect approach to obtain the diagnosed prevalence of AF from the total prevalence of AF.

Know more about this report at: http://mrr.cm/Zqp

Find all Healthcare Reports at : http://www.marketresearchreports.com/healthcare

Migraine - Current and Future Players, New Report Launched

“PharmaPoint: Migraine - Current and Future Players” report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Migraine Market. The report identifies and analyses the key companies shaping and driving the global Migraine market. The report provides insight into the competitive Migraine landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.

Scope

• Investigation of current and future market competition for Migraine
• Competitor assessment
• Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
• Strategic assessment of Migraine sector through market impact analysis, future market scenario and company analysis

Reasons to buy

• Gain a high level view of the trends shaping and driving Migraine market
• Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
• Create an effective counter-strategy to gain a competitive advantage against those currently in the market
• What’s the next big thing in the global Migraine market landscape? Identify, understand and capitalize

Spanning Over 54 pages, 34 tables, 2 figures, “PharmaPoint - Migraine - Current and Future Players” report covering the Market Outlook, Current and Future Players, Appendix. The report covered 15 companies - GlaxoSmithKline, AstraZeneca Merck, Vernalis, Almirall, Pfizer, Zogenix, NuPathe, Allergan, RedHill Biopharma, OptiNose, CoLucid Pharmaceuticals, SUDA, Revance Therapeutics, NeurAxon.

Know more about this report at: http://mrr.cm/ZTw

Migraine - US Drug Forecast and Market Analysis to 2023, New Report Launched

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

The US migraine market is the largest given its population size and high drug prices. The main growth driver during this period will be Allergan’s Botox, in addition to the launch of new combinations of drug and device and new classes of acute therapy. Historically the triptans have dominated the acute migraine segment and although the gold standard, GSK’s Imitrex, expired in 2008, it has remained as one of the most popular triptans among physicians. A recent trend in this segment is the development of devices that can deliver drugs in a more effective way, such as Sumavel DosePro, a needle-free injection of sumatriptan.

Scope

• Overview of Migraine including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for the top drugs in the US from 2012-2023.
• Analysis of the impact of key events as well the drivers and restraints affecting the US Migraine market.

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for Migraine
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of drug performance
• Obtain sales forecast for drugs from 2012-2023 in the US

Spanning Over 143 pages “PharmaPoint: Migraine - US Drug Forecast and Market Analysis to 2023” report provide the Disease Overview, Disease Management, Competitive AssessmentOpportunity and Unmet Need, Pipeline Assessment, Market Outlook, Appendix.  

Know more about this report at: http://mrr.cm/ZTp

Find other Pharma and Healthcare Reports at : http://www.marketresearchreports.com/pharma-healthcare

For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter